We serve Chemical Name:Fmoc-(R)-3-Amino-2-methylpropanoic acid CAS:211682-15-4 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.
Chemical Name:Fmoc-(R)-3-Amino-2-methylpropanoic acid
CAS.NO:211682-15-4
Synonyms:FMOC-R-AMPA-OH;AmbotzFAA1761;FMOC-R-3-AMINOISOBUTYRIC ACID
Molecular Formula:C19H19NO4
Molecular Weight:325.35800
HS Code:2924299090
Physical and Chemical Properties:
Melting point:N/A
Boiling point:555.3ºC at 760 mmHg
Density:1.255g/cm3
Index of Refraction:1.598
PSA:75.63000
Exact Mass:325.13100
LogP:3.63670
Material Safety Information (Applicable for Hazard Chemicals)
RIDADR:NONH for all modes of transpor
Packing Group:
Contact us for information like FMOC-R-AMPA-OH chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,FMOC-R-3-AMINOISOBUTYRIC ACID physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,AmbotzFAA1761 Use and application,FMOC-R-3-AMINOISOBUTYRIC ACID technical grade,usp/ep/jp grade.
Related News: The GLOW trial doesn’t yet have the answer to that question, but Tendler pointed to encouraging early evidence from the regimen’s phase 2 trial, dubbed CAPTIVATE. Among eight patients who progressed after stopping the fixed-duration combo, six responded to subsequent Imbruvica monotherapy, while the other two didn’t have a response report, according to data presented at the recent American Society of Clinical Oncology annual meeting. Fmoc-(R)-3-Amino-2-methylpropanoic acid manufacturer The drug substance is an active product that has completed the synthetic route, and the intermediate is a product in one place in the synthetic route. Fmoc-(R)-3-Amino-2-methylpropanoic acid supplier The drug substance is an active product that has completed the synthetic route, and the intermediate is a product in one place in the synthetic route. Fmoc-(R)-3-Amino-2-methylpropanoic acid vendor The drug substance is an active product that has completed the synthetic route, and the intermediate is a product in one place in the synthetic route. Fmoc-(R)-3-Amino-2-methylpropanoic acid factory The GLOW trial doesn’t yet have the answer to that question, but Tendler pointed to encouraging early evidence from the regimen’s phase 2 trial, dubbed CAPTIVATE. Among eight patients who progressed after stopping the fixed-duration combo, six responded to subsequent Imbruvica monotherapy, while the other two didn’t have a response report, according to data presented at the recent American Society of Clinical Oncology annual meeting.
